Drugs / HER2 Specific CAR T Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04903080 | Jul 2022 → Mar 2033 expected | ependymoma | Children's Oncology Group | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2 Specific CAR T Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04903080 ↗ |
| Known as | HER2 CAR | “HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.” NCT04903080 ↗ |
| Action | Deplete | “These HER2-specific CAR T cells may be able to target and kill ependymoma tumors that express HER2.” NCT04903080 ↗ |
| Modality | Cell therapy | “type of immune therapy called HER2 CAR T cells” NCT04903080 ↗ |
| Route | Intravenous | “safety of intravenous injection of HER2-specific CAR T cells” NCT04903080 ↗ |